SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT

被引：0
|
作者：
Van Cutsem, E. [1 ]
Berry, S. [2 ]
Michael, M. [3 ]
Kretzschmar, A. [4 ]
Rivera, F. [5 ]
DiBartolomeo, M. [6 ]
Mazier, M. [7 ]
Andre, N.
Cunningham, D. [8 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[4] Charite Campus Buch, Berlin, Germany
[5] Hosp M Valdecilla, Santander, Spain
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] PARAXEL Int, Biostat & Programming, Paris, France
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [31] SAFETY AND EFFICACY OF BEVACIZUMAB WITH FIRST-LINE FOLFIRI FOR METASTATIC COLORECTAL CANCER: SINGLE CENTER EXPERIENCE
    De Sanctis, R.
    Longo, F.
    Gori, B.
    Zivi, A.
    Del Signore, E.
    Proietti, E.
    De Filippis, L.
    Stumbo, L.
    Quadrini, S.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 145 - 145
  • [32] Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: Single center experience
    Longo, F.
    De Sanctis, R.
    Quadrini, S.
    Stumbo, L.
    Del Signore, E.
    Gori, B.
    De Filippis, L.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 91 - 92
  • [33] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [34] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 128 - 128
  • [35] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
    Kozloff, M.
    Hainsworth, J.
    Badrinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sarkar, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [36] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    ANNALS OF ONCOLOGY, 2014, 25
  • [37] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [38] Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Gerger, Armin
    El-Khoueiry, Anthony
    Zhang, Wu
    Yang, Dongyun
    Singh, Harpreet
    Bohanes, Pierre
    Ning, Yan
    Winder, Thomas
    LaBonte, Melissa J.
    Wilson, Peter M.
    Benhaim, Leonor
    Paez, David
    El-Khoueiry, Rita
    Absenger, Gudrun
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5783 - 5792
  • [39] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [40] First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
    Zhou, Yu-Wen
    Long, Yi-Xiu
    Chen, Ye
    Liu, Ji-Yan
    Pu, Dan
    Huang, Jia-Yan
    Bi, Feng
    Li, Qiu
    Gou, Hong-Feng
    Qiu, Meng
    CANCER MEDICINE, 2021, 10 (10): : 3388 - 3402
12345